Senores Pharma has announced that the United States Food and Drug Administration (USFDA) has issued an Establishment Inspection Report (EIR) for manufacturing facility of Havix Group Inc., doing business as Aavis Pharmaceuticals and a material subsidiary of the company, in Hoschton, Georgia. team had earlier reported in July that the USFDA conducted an inspection of its facility from July 21 and July 25, 2025. The inspection resulted in three minor, 483 observations. Read also:Senores Pharma arm facility gets 3 USFDA observations According to the latest filing to the BSE, Havix has addressed and resolved all the observations. Senores Pharmaceuticals Limitedis a global, research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms. The companies’ current portfolio includes 61 ANDA and 22 CMO/CDMO commercial products that are permitted for distribution in the USA. Senores is also engaged in the development and manufacturing of complex generics certified by global food and drugs authorities and delivers generic drugs for emerging markets, catering to more than 40 countries. The company currently has approval from regulatory bodies of more than 10 countries for its manufacturing facility in Chhatral for emerging markets with over 280 product registrations and 630 product applications. Senores also manufactures critical care injectables and Active Pharmaceutical Ingredients (“API”). Senores has 2 manufacturing facilities for formulations – one in Atlanta, US which is USFDA approved and DEA, TAA & BAA compliant for controlled substances and government supplies & other is in Chhatral, Ahmedabad, India approved by WHO-GMP to cater to emerging markets. The company also has 2 manufacturing facilities for API in India, both located around Ahmedabad, with one in Chhatral and the other in Naroda. Read also:Senores Pharma to acquire two products of USFDA approved ANDAs from Teva Pharma USA